JP Morgan Chase’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

JP Morgan Chase’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-101,586	Closed	-$10.9M	–	7496
2023 Q1	$10.9M	Sell	101,586 -25,489	-20%	-$2.93M	﹤0.01%	2197
2022 Q4	$14M	Buy	127,075 +44,966	+55%	+$2.92M	﹤0.01%	1950
2022 Q3	$4.84M	Sell	82,109 -291	-0.4%	-$13.3K	﹤0.01%	2770
2022 Q2	$2.33M	Sell	82,400 -527	-0.6%	-$15.3K	﹤0.01%	3410
2022 Q1	$3.13M	Buy	82,927 +67,975	+455%	+$2.69M	﹤0.01%	3398
2021 Q4	$591K	Buy	14,952 +10,606	+244%	+$332K	﹤0.01%	4716
2021 Q3	$103K	Sell	4,346 -2,476	-36%	-$58.4K	﹤0.01%	5553
2021 Q2	$168K	Buy	+6,822	New	+$152K	﹤0.01%	5327

Other funds holding RXDX

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

JP Morgan Chase's RXDX Position: Q2 2023 in Review

JP Morgan Chase sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 101,586 shares — an estimated $10.9M sold.

JP Morgan Chase first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $14M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

JP Morgan Chase reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
JP Morgan Chase sold 101,586 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $10.9M.
JP Morgan Chase first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
JP Morgan Chase's Prometheus Biosciences, Inc. Common Stock position peaked at $14M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.